From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy

SIMPLE SUMMARY: Immune control inhibitor drugs (anti-PD1/PD-L1/CTLA-4) (ICIs) are showing efficacy in the treatment of lung cancer. Currently the only biomarker with clinical utility for ICIs, such as the expression of PDL1, does not appear to be perfect or effective. Our working group is conducting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Sesma, Andrea, Pardo, Julián, Cruellas, Mara, Gálvez, Eva M., Gascón, Marta, Isla, Dolores, Martínez-Lostao, Luis, Ocáriz, Maitane, Paño, José Ramón, Quílez, Elisa, Ramírez, Ariel, Torres-Ramón, Irene, Yubero, Alfonso, Zapata, María, Lastra, Rodrigo
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7602200/
https://ncbi.nlm.nih.gov/pubmed/33066479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102974
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados